Skip to content
The Nexus
DossierENTITY

peptide therapies

Coverage of peptide therapies in the Nexus archive.

Earliest in view: Jul 8 · 10:00 UTCMost recent: Jul 24 · 10:43 UTC
Co-mentioned in this coverage
Recent coverage
  • HEALTHJul 24 · 10:43 UTCNPR HEALTH
    FDA panel backs easier access to peptides

    Advisers to the Food and Drug Administration voted to allow specialized pharmacies to produce peptide therapies, despite recommendations from agency scientists against the move. The decision aims to ease access to these popular treatments.

  • HEALTHJul 14 · 18:46 UTCFORTUNE
    Trust in the FDA is collapsing. It’s time to get really transparent about our food and our drugs

    Trust in the FDA has dropped from 75% to 50% in two years, driven by public concerns about political interference in decision-making. HHS Secretary Robert F. Kennedy Jr. has publicly criticized the FDA as 'corrupt' and pressured it to loosen oversight of therapies, conflicting with scientific recommendations.

  • HEALTHJul 8 · 10:00 UTCNPR HEALTH
    What's behind the push to make peptide therapies more readily available

    Peptide therapies, marketed for longevity and wellness benefits, are sold through a grey market online. Compounding pharmacies argue they should be allowed to produce these unproven therapies legally to meet demand.

  • HEALTHJul 8 · 10:00 UTCNPR NEWS
    What's behind the push to make peptide therapies more readily available

    Peptide therapies, marketed for longevity and wellness, are sold through an online grey market despite lacking proven efficacy. Compounding pharmacies argue they should be legally permitted to produce these therapies to meet demand.